The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease

BACKGROUND: Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Decramer, Marc L, Hanania, Nicola A, Lötvall, Jan O, Yawn, Barbara P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558319/
https://www.ncbi.nlm.nih.gov/pubmed/23378756
http://dx.doi.org/10.2147/COPD.S39018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558319/
https://www.ncbi.nlm.nih.gov/pubmed/23378756
http://dx.doi.org/10.2147/COPD.S39018

Ejemplares similares